Durvalumab vs Levodopa

Durvalumab vs Levodopa: Overview

This comparison examines the pharmacological differences between Durvalumab and Levodopa.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Levodopa: Metabolic precursor of dopamine that crosses the BBB.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Levodopa — 1.5 hours.

Chemical Properties

Molecular Formula: Levodopa — C9H11NO4.

Molecular Weight: Levodopa — 197.1880 g/mol.

Type: Durvalumab — Antibody; Levodopa — Small molecule.